加拿大-话题@MedSci

#加拿大#

187篇内容 | 4027人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1312647, encodeId=389e131264ec8, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, objectTitle=大剂量吸入一氧化氮治疗COVID-19肺部并发症的临床试验：将在加拿大进行, objectType=article, longId=191305, objectId=383a191305e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=383a191305e2, replyNumber=0, likeNumber=53, createdTime=2020-04-04, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=383a191305e2, moduleTitle=大剂量吸入一氧化氮治疗COVID-19肺部并发症的临床试验：将在加拿大进行, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=383a191305e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312646, encodeId=92351312646d0, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, objectTitle=Clinica Chimica Acta：加拿大一组慢性肾病患者的法布里病高危筛查, objectType=article, longId=190367, objectId=dcc419036ec9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcc419036ec9, replyNumber=0, likeNumber=61, createdTime=2020-03-21, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcc419036ec9, moduleTitle=Clinica Chimica Acta：加拿大一组慢性肾病患者的法布里病高危筛查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcc419036ec9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312645, encodeId=f4ed13126456b, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, objectTitle=“钻石公主”号邮轮：至少32名加拿大人在感染新冠肺炎, objectType=article, longId=188353, objectId=57c2188353a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57c2188353a3, replyNumber=0, likeNumber=61, createdTime=2020-02-20, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57c2188353a3, moduleTitle=“钻石公主”号邮轮：至少32名加拿大人在感染新冠肺炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57c2188353a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312644, encodeId=b121131264485, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, objectTitle=Lancet: 加拿大已出院病例，但其仍携带新冠病毒..., objectType=article, longId=188203, objectId=cdd91882036b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdd91882036b, replyNumber=0, likeNumber=48, createdTime=2020-02-17, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdd91882036b, moduleTitle=Lancet: 加拿大已出院病例，但其仍携带新冠病毒..., moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdd91882036b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312643, encodeId=cf271312643ea, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, objectTitle=加拿大P4实验室创始人参会猝死，曾是抗击Sars、艾滋、埃博拉英雄, objectType=article, longId=188161, objectId=77431881618c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77431881618c, replyNumber=0, likeNumber=112, createdTime=2020-02-17, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77431881618c, moduleTitle=加拿大P4实验室创始人参会猝死，曾是抗击Sars、艾滋、埃博拉英雄, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77431881618c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312642, encodeId=2a151312642c3, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, objectTitle=2020 加拿大实践指南：儿童和青少年进食障碍的治疗, objectType=article, longId=188084, objectId=0e5d18808434, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e5d18808434, replyNumber=0, likeNumber=38, createdTime=2020-02-16, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e5d18808434, moduleTitle=2020 加拿大实践指南：儿童和青少年进食障碍的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e5d18808434)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312641, encodeId=5f3713126414a, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, objectTitle=2019 加拿大卒中更佳实践建议：卒中后康复，恢复和社区参与-part2, objectType=article, longId=187486, objectId=e3a318e486c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3a318e486c3, replyNumber=0, likeNumber=31, createdTime=2020-02-06, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3a318e486c3, moduleTitle=2019 加拿大卒中更佳实践建议：卒中后康复，恢复和社区参与-part2, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3a318e486c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312640, encodeId=eaee131264084, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, objectTitle=2019 加拿大卒中更佳实践建议：卒中后康复，恢复和社区参与-part1, objectType=article, longId=187485, objectId=884718e4854e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=884718e4854e, replyNumber=0, likeNumber=29, createdTime=2020-02-06, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=884718e4854e, moduleTitle=2019 加拿大卒中更佳实践建议：卒中后康复，恢复和社区参与-part1, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=884718e4854e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312639, encodeId=a5a813126395d, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, objectTitle=加拿大卫生部批准卡那列净的新适应症，以降低2型糖尿病患者肾病相关风险, objectType=article, longId=186986, objectId=f35818698644, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f35818698644, replyNumber=0, likeNumber=51, createdTime=2020-01-31, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f35818698644, moduleTitle=加拿大卫生部批准卡那列净的新适应症，以降低2型糖尿病患者肾病相关风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f35818698644)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312638, encodeId=0b041312638e1, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, objectTitle=加拿大卫生部批准Drax Exametazime用于核医学成像, objectType=article, longId=186911, objectId=42d8186911ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42d8186911ac, replyNumber=0, likeNumber=67, createdTime=2020-01-30, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42d8186911ac, moduleTitle=加拿大卫生部批准Drax Exametazime用于核医学成像, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42d8186911ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312637, encodeId=d194131263e77, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, objectTitle=Ann Fam Med：加拿大随机对照试验称，早晨或晚上服用华法林无差别, objectType=article, longId=186800, objectId=362218680035, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=362218680035, replyNumber=0, likeNumber=61, createdTime=2020-01-28, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=362218680035, moduleTitle=Ann Fam Med：加拿大随机对照试验称，早晨或晚上服用华法林无差别, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=362218680035)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312636, encodeId=5ffe1312636fe, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, objectTitle=UCB的抗TNF单抗赛妥珠单抗在加拿大获准用于治疗非放射性轴突性脊柱关节炎, objectType=article, longId=186376, objectId=0af51863e634, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0af51863e634, replyNumber=0, likeNumber=50, createdTime=2020-01-18, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0af51863e634, moduleTitle=UCB的抗TNF单抗赛妥珠单抗在加拿大获准用于治疗非放射性轴突性脊柱关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0af51863e634)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312635, encodeId=56f91312635ac, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, objectTitle=加拿大研究称，与氯吡格雷相比，替格瑞洛致大出血风险增加51%, objectType=article, longId=186361, objectId=f709186361d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f709186361d9, replyNumber=0, likeNumber=83, createdTime=2020-01-18, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f709186361d9, moduleTitle=加拿大研究称，与氯吡格雷相比，替格瑞洛致大出血风险增加51%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f709186361d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312634, encodeId=ca72131263441, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, objectTitle=加拿大研究：首次卒中后患者30天内新发心脏病风险升高20多倍, objectType=article, longId=186175, objectId=37461861e59b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37461861e59b, replyNumber=0, likeNumber=71, createdTime=2020-01-14, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37461861e59b, moduleTitle=加拿大研究：首次卒中后患者30天内新发心脏病风险升高20多倍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37461861e59b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312633, encodeId=5c1d13126339f, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, objectTitle=Stroke：加拿大研究：首次卒中后患者30天内新发心脏病风险升高20多倍, objectType=article, longId=186118, objectId=3fa81861185f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fa81861185f, replyNumber=0, likeNumber=74, createdTime=2020-01-13, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fa81861185f, moduleTitle=Stroke：加拿大研究：首次卒中后患者30天内新发心脏病风险升高20多倍, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fa81861185f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312632, encodeId=449a131263282, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, objectTitle=艾伯维的口服JAK抑制剂RINVOQ获得加拿大批准，用于治疗中度至重度活动性类风湿性关节炎, objectType=article, longId=185935, objectId=6a1818593535, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a1818593535, replyNumber=0, likeNumber=52, createdTime=2020-01-10, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a1818593535, moduleTitle=艾伯维的口服JAK抑制剂RINVOQ获得加拿大批准，用于治疗中度至重度活动性类风湿性关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a1818593535)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312631, encodeId=58b6131263140, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, objectTitle=加拿大麻醉医师学会：麻醉实践指南（2020修订版）, objectType=article, longId=184281, objectId=cb7318428155, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb7318428155, replyNumber=0, likeNumber=30, createdTime=2019-12-07, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb7318428155, moduleTitle=加拿大麻醉医师学会：麻醉实践指南（2020修订版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb7318428155)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312630, encodeId=d9881312630dc, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, objectTitle=加拿大指南称：正常人不建议常规查甲状腺功能, objectType=article, longId=184116, objectId=af27184116c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af27184116c7, replyNumber=0, likeNumber=52, createdTime=2019-12-05, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af27184116c7, moduleTitle=加拿大指南称：正常人不建议常规查甲状腺功能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af27184116c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312629, encodeId=551613126295f, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, objectTitle=加拿大卫生部批准OFEV（nintedanib）用以缓解系统性硬化症相关ILD患者肺功能下降, objectType=article, longId=183715, objectId=fe2f183e1514, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe2f183e1514, replyNumber=0, likeNumber=79, createdTime=2019-11-29, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe2f183e1514, moduleTitle=加拿大卫生部批准OFEV（nintedanib）用以缓解系统性硬化症相关ILD患者肺功能下降, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe2f183e1514)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1312628, encodeId=ef271312628b0, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, objectTitle=TAKHZYRO（lanadelumab注射液）获得加拿大药物专家委员会的积极推荐，用于常规预防遗传性血管性水肿（HAE）发作, objectType=article, longId=183553, objectId=65371835530b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65371835530b, replyNumber=0, likeNumber=68, createdTime=2019-11-26, rootId=0, userName=shanyongle, userId=279b407, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65371835530b, moduleTitle=TAKHZYRO（lanadelumab注射液）获得加拿大药物专家委员会的积极推荐，用于常规预防遗传性血管性水肿（HAE）发作, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65371835530b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

加拿大

2020-05-29

shanyongle (审核中...)

前往app查看评论内容

#加拿大#

大剂量吸入一氧化氮治疗COVID-19肺部并发症的临床试验：将在加拿大进行

2020-04-04

shanyongle (审核中...)

前往app查看评论内容

#加拿大#

Clinica Chimica Acta：加拿大一组慢性肾病患者的法布里病高危筛查

2020-03-21

shanyongle (审核中...)

前往app查看评论内容

#加拿大#

“钻石公主”号邮轮：至少32名加拿大人在感染新冠肺炎

2020-02-20

shanyongle (审核中...)

前往app查看评论内容

#加拿大#

Lancet: 加拿大已出院病例，但其仍携带新冠病毒...

2020-02-17

shanyongle (审核中...)

前往app查看评论内容

#加拿大#

加拿大P4实验室创始人参会猝死，曾是抗击Sars、艾滋、埃博拉英雄

2020-02-17

shanyongle (审核中...)

前往app查看评论内容

#加拿大#

2020 加拿大实践指南：儿童和青少年进食障碍的治疗

2020-02-16

shanyongle (审核中...)

前往app查看评论内容

#加拿大#

2019 加拿大卒中更佳实践建议：卒中后康复，恢复和社区参与-part2

2020-02-06

shanyongle (审核中...)

前往app查看评论内容

#加拿大#

2019 加拿大卒中更佳实践建议：卒中后康复，恢复和社区参与-part1

2020-02-06

shanyongle (审核中...)

前往app查看评论内容

#加拿大#

加拿大卫生部批准卡那列净的新适应症，以降低2型糖尿病患者肾病相关风险

2020-01-31

shanyongle (审核中...)

前往app查看评论内容

#加拿大#

加拿大卫生部批准Drax Exametazime用于核医学成像

2020-01-30

shanyongle (审核中...)

前往app查看评论内容

#加拿大#

Ann Fam Med：加拿大随机对照试验称，早晨或晚上服用华法林无差别

2020-01-28

shanyongle (审核中...)

前往app查看评论内容

#加拿大#

UCB的抗TNF单抗赛妥珠单抗在加拿大获准用于治疗非放射性轴突性脊柱关节炎

2020-01-18

shanyongle (审核中...)

前往app查看评论内容

#加拿大#

加拿大研究称，与氯吡格雷相比，替格瑞洛致大出血风险增加51%

2020-01-18

shanyongle (审核中...)

前往app查看评论内容

#加拿大#

加拿大研究：首次卒中后患者30天内新发心脏病风险升高20多倍

2020-01-14

shanyongle (审核中...)

前往app查看评论内容

#加拿大#

Stroke：加拿大研究：首次卒中后患者30天内新发心脏病风险升高20多倍

2020-01-13

shanyongle (审核中...)

前往app查看评论内容

#加拿大#

艾伯维的口服JAK抑制剂RINVOQ获得加拿大批准，用于治疗中度至重度活动性类风湿性关节炎

2020-01-10

shanyongle (审核中...)

前往app查看评论内容

#加拿大#

加拿大麻醉医师学会：麻醉实践指南（2020修订版）

2019-12-07

shanyongle (审核中...)

前往app查看评论内容

#加拿大#

加拿大指南称：正常人不建议常规查甲状腺功能

2019-12-05

shanyongle (审核中...)

前往app查看评论内容

#加拿大#

加拿大卫生部批准OFEV（nintedanib）用以缓解系统性硬化症相关ILD患者肺功能下降

2019-11-29

shanyongle (审核中...)

前往app查看评论内容

#加拿大#

TAKHZYRO（lanadelumab注射液）获得加拿大药物专家委员会的积极推荐，用于常规预防遗传性血管性水肿（HAE）发作

2019-11-26

科室
- - 订阅+
  - 更多科室
工具
服务